Paradigm Biopharmaceuticals Ltd
ASX:PAR

Watchlist Manager
Paradigm Biopharmaceuticals Ltd Logo
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Watchlist
Price: 0.27 AUD -3.57% Market Closed
Updated: May 20, 2024
PAR
/
Income Statement
/
Cost of Revenue

Paradigm Biopharmaceuticals Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Paradigm Biopharmaceuticals Ltd
Cost of Revenue Peer Comparison

Comparables:
IMM
MSB
CSL
CUV
TLX

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Cost of Revenue
-AU$11.5k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Immutep Ltd
ASX:IMM
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Cost of Revenue
-$21.7m
CAGR 3-Years
15%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Cost of Revenue
-$6.9B
CAGR 3-Years
-19%
CAGR 5-Years
-14%
CAGR 10-Years
-11%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Cost of Revenue
AU$8.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Cost of Revenue
-AU$188.2m
CAGR 3-Years
-353%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Paradigm Biopharmaceuticals Ltd's Cost of Revenue?
Cost of Revenue
-11.5k AUD

Based on the financial report for Dec 31, 2023, Paradigm Biopharmaceuticals Ltd's Cost of Revenue amounts to -11.5k AUD.

What is Paradigm Biopharmaceuticals Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 1Y
86%

Over the last year, the Cost of Revenue growth was 86%.

ALPHA SPREAD
Join more than 138,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.